122 related articles for article (PubMed ID: 38008375)
1. Systemic Chemotherapy with or without Hepatic Arterial Infusion Chemotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Oligometastasis: A Propensity Score-Matched Analysis.
Li Z; Xu R; Chang X; Sun P
J Vasc Interv Radiol; 2024 Mar; 35(3):416-427.e17. PubMed ID: 38008375
[TBL] [Abstract][Full Text] [Related]
2. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
3. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
Jiang N; Zhang Z; Yin X; Qiu H; Yan W; Hao Y; Yang W; Li H; Xu A; Mu K
Radiol Med; 2024 Apr; 129(4):631-642. PubMed ID: 38355907
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice.
Lin LW; Ke K; Chen R; Yang WZ; Huang N; Wu ZZ
Front Immunol; 2023; 14():1286771. PubMed ID: 38288113
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
[No Abstract] [Full Text] [Related]
6. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Ishii M; Itano O; Morinaga J; Shirakawa H; Itano S
PLoS One; 2022; 17(4):e0266707. PubMed ID: 35452492
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
8. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival.
Soares KC; Jolissaint JS; McIntyre SM; Seier KP; Gönen M; Sigel C; Nasar N; Cercek A; Harding JJ; Kemeny NE; Connell LC; Koerkamp BG; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Wei AC; Jarnagin WR
Cancer Med; 2023 Jun; 12(11):12272-12284. PubMed ID: 37062071
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Huang P; Huang X; Zhou Y; Yang G; Sun Q; Shi G; Chen Y
Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
[TBL] [Abstract][Full Text] [Related]
11. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.
Jolissaint JS; Soares KC; Seier KP; Kundra R; Gönen M; Shin PJ; Boerner T; Sigel C; Madupuri R; Vakiani E; Cercek A; Harding JJ; Kemeny NE; Connell LC; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Wei AC; Jarnagin WR
Clin Cancer Res; 2021 Jul; 27(14):4101-4108. PubMed ID: 33963001
[TBL] [Abstract][Full Text] [Related]
14. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
Front Immunol; 2022; 13():940009. PubMed ID: 35874708
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study.
Wu JZ; Li CL; Shi HB; Liu S; Yang W; Zhou WZ
Jpn J Radiol; 2022 Apr; 40(4):396-403. PubMed ID: 34727330
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhao R; Zhou J; Miao Z; Xiong X; Wei W; Li S; Guo R
Front Immunol; 2024; 15():1397827. PubMed ID: 38799453
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.
Chen S; Yuan B; Yu W; Wang X; He C; Chen C
J Surg Oncol; 2022 Dec; 126(7):1205-1214. PubMed ID: 35856502
[TBL] [Abstract][Full Text] [Related]
19. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis.
Yan X; Zhuang LP; Ning ZY; Wang P; Meng ZQ
Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):81-88. PubMed ID: 34937481
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma.
Yang Z; Fu Y; Wu W; Hu Z; Pan Y; Wang J; Chen J; Hu D; Zhou Z; Chen M; Zhang Y
Front Pharmacol; 2023; 14():1234342. PubMed ID: 37731737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
